Healthy Clinical Trial
— KS-2Official title:
Investigation of GLP-2 Mechanism of Action (KS-2)
Verified date | January 2020 |
Source | University of Copenhagen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Effects of GLP-2 and GIP on bone remodeling in healthy young men.
Status | Completed |
Enrollment | 10 |
Est. completion date | March 15, 2018 |
Est. primary completion date | March 15, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 20 Years to 40 Years |
Eligibility |
Inclusion Criteria: Age between 20 and 40 years old Caucasian Healthy BMI between 18.5 and 24.9 kg/m2. Exclusion Criteria: Chronic disease Smoking Medication Weight change more than 3 kg whitin the last 3 months Overweight surgery Intestinal surgery Hgb<8,0 mmol/L Decreased renal function. |
Country | Name | City | State |
---|---|---|---|
Denmark | Hvidovre University Hospital | Hvidovre |
Lead Sponsor | Collaborator |
---|---|
University of Copenhagen | Hvidovre University Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Heart rate | Before blood sampling | From -10 minutes to 240 minutes. | |
Other | Blood pressure | Before blood sampling | From -10 minutes to 240 minutes. | |
Primary | Bone resorption | C-terminal telopeptide (CTX) is a marker of bone resorption. Measured in serum. | From -10 minutes to 240 minutes. | |
Primary | Bone formation | P1NP is a marker of bone formation. Measured in serum. | From -10 minutes to 240 minutes. | |
Secondary | Parathyroid hormone | PTH is a bone marker | From -10 minutes to 240 minutes. | |
Secondary | Calcium | Measured in serum. | From -10 minutes to 240 minutes. | |
Secondary | GIP | Intact and total GIP. | From -10 minutes to 240 minutes. | |
Secondary | GLP-2 | Intact GLP-2 | From -10 minutes to 240 minutes. | |
Secondary | Glucose | Measured in serum. | From -10 minutes to 240 minutes. | |
Secondary | Insulin | Measured in serum. | From -10 minutes to 240 minutes. | |
Secondary | C-peptide | Measured in serum. | From -10 minutes to 240 minutes. | |
Secondary | Sclerostin | Bone marker. | From -10 minutes to 240 minutes. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |